Clinical trials: Leukoencephalopathy, Progressive Multifocal
PML, AIDS
Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome
This study will identify genetic factors associated with the development of progressive multifocal leukoencephalopathy (PML) in patients with acquired immunodeficiency syndrome (AIDS).
- Trial name
- NCT00342602
- Where
- 6 sites in United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Progressive Multifocal Leukoencephalopathy
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML) is a rare viral infection of the central nervous system (CNS) occurring in immunocompromised patients.
- Trial name
- ICIP (NCT04453917)
- Testing
- Collection of blood and urine, Spinal tap, Brain MRI
- Where
- 3 sites in France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Toulouse
HIV Infections, Leukoencephalopathy, Progressive Multifocal
A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion…
- Trial name
- NCT00002274
- Testing
- Didanosine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Progressive Multifocal Leukoencephalopathy
Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells
Background: Progressive Multifocal Leukoencephalopathy (PML) is a brain infection in people with a weakened immune system. Researchers think polyoma virus specific T cells (PyVST) therapy can treat PML.
- Trial name
- NCT02694783
- Testing
- PyVST
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Progressive Multifocal Leukoencephalopathy
Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)
This is a continuation of our previous studies on Progressive Multifocal Leukoencephalopathy (PML). We will focus on the role of inflammation in PML, and define prognostic markers of disease evolution.
- Trial name
- NCT01132053
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Beth Israel Deaconess Medical Center
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
Background: Multiple sclerosis (MS) and progressive multifocal leukoencephalopathy (PML) are disorders that affect the central nervous system (CNS). The CNS includes the brain, spinal cord, and optic nerves.
- Conditions
- Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
- Trial name
- NCT05849467
- Testing
- 89 Zr-Df-crefmirlimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Progressive Multifocal Leukoencephalopathy
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
The primary objective of the study was to explore whether mefloquine can delay or stop progression of progressive multifocal leukoencephalopathy (PML) as measured by JC virus (human polyomavirus or JCV) deoxyribonucleic acid…
- Trial name
- NCT00746941
- Testing
- mefloquine
- Where
- 12 sites in United States, Brazil and 3 more
- Volunteers
- 37 people
- Sponsor
- Biogen
Progressive Multifocal Leukoencephalopathy
A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML
This is a randomized, double-blinded, Phase 2 trial in patients with PML due to JCPyV. Patients will receive treatment with a matched virus-specific T-cell product (CE VST01-JC) or placebo, and will then be monitored for response…
- Trial name
- ASCEND-JC (NCT05541549)
- Testing
- CE-VST01-JC
- Volunteers
- 60 people
- Sponsor
- Cellevolve Bio Inc
Multiple Sclerosis
Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
Under the escalation treatment strategy when a patient displays breakthrough disease parameters under first line therapy, MS physicians are allowed by the EMEA to switch for Natalizumab (NTZ) or fingolimod (FGL).
- Trial name
- BEST-MS (NCT01981161)
- Testing
- biological samples and clinical data
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 307 people
- Sponsor
- University Hospital, Toulouse
Progressive Multifocal Leukoencephalopathy
Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
Background: Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal brain infection caused by the JC virus. The JC virus is common. More than half of adults have been exposed to it.
- Trial name
- NCT07511049
- Testing
- Brincidofovir
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Progressive Multifocal Leukoencephalopathy
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
Background: Progressive multifocal leukoencephalopathy (PML) is a brain infection. It is caused by a virus. PML can happen in people with a weakened immune system.
- Trial name
- NCT04781309
- Testing
- NT-I7
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Progressive Multifocal Leucoencephalopathy (PML)
T-cell Therapy in Patients With PML
There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment.
- Trial name
- NCT06990087
- Testing
- Application of T-lymphocytes
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Hannover Medical School